COMMUNIQUÉS West-GlobeNewswire

Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients
28/07/2026
Analysis projects national average cost savings of ~$24,000 per episode alongside improved ventilator weaning outcomes EXTON, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Lungpacer Medical today announced results from a new [...]
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
28/07/2026
CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
28/07/2026
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in [...]
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
28/07/2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second [...]
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
28/07/2026
Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% Raising both FY26 [...]
Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687
28/07/2026
The Phase 2a study will evaluate AT7687 as a differentiated combination treatment approach for people living with obesity and type 2 diabetes A 13-week study of 150 randomized participants receiving either once-weekly [...]
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
28/07/2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
28/07/2026
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level [...]
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
28/07/2026
LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
28/07/2026
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, [...]
Transactions in connection with share buy-back program
28/07/2026
Company announcement no. 27 - 26 28 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC
28/07/2026
Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC Non-dilutive Biomedical Catalyst funding from Innovate UK will support the advancement of [...]
Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch
28/07/2026
New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders Builds on the €50m secured in [...]
Aqua free Supports Drinking Water Project in Tanzania
28/07/2026
Hamburg, 28.07.2026 - Access to safe water is still not given in many parts of the world. In Lower Moshi, a region south of Mount Kilimanjaro in Tanzania, communities and schools struggle with contaminated drinking [...]
Aqua free soutient un projet d’accès à l’eau potable en Tanzanie
28/07/2026
Hamburg, 28.07.2026 - Dans de nombreuses régions du monde, l’accès à une eau potable sûre est encore loin d’être garanti. Dans le Lower Moshi, une région située au sud du Kilimandjaro, en Tanzanie, les communautés [...]
Tensive reports pivotal 12-month clinical trial data confirming REGENERA™ delivers natural breast reconstruction after lumpectomy
28/07/2026
Good-to-excellent cosmetic outcomes 30 of 94 patients enrolled have now reached 24 months of follow-up High surgeon satisfaction sustained through study to date Improvements in patient-reported breast satisfaction and [...]
Rapid Nutrition Expands Owned-Brand Portfolio Through AI-Driven Commercial Intelligence
28/07/2026
Initial rollout of the Premium Nutrition Pantry demonstrates the Company's strategy to accelerate owned-brand expansion, strengthen vertical integration and support long-term revenue growth LONDON, July 28, 2026 (GLOBE [...]
ARCPOINT PROVIDES UPDATE ON MANAGEMENT CEASE TRADE ORDER APPLICATION AND DELAY IN FILING ANNUAL FINANCIAL STATEMENTS
28/07/2026
GREENVILLE, South Carolina, July 27, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) provides an update further to its news release dated July 15, 2026 (the “ MCTO Application [...]
BurnTide Launch 2026: New Weight Loss Support ACV Gummies In The USA, AU, UK | Burntide Supplement Facts And Highlights Ingredients.
28/07/2026
Burntide is announcing an effective and updated weight loss support supplement, Burntide Gummies, analyzing the natural ingredient profile, supplement facts, manufacturing information, Customer Service Support Details, [...]

Pages